Ubs Group Ag Candel Therapeutics, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 156,806 shares of CADL stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

156,806

Previous 9,446 1560.03%

Holding current value

$1.82 Million

Previous $65,000 1993.85%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.96 - $9.96 $583,545 - $1.47 Million	147,360 Added 1560.03%	156,806 $1.36 Million
Q3 2024 Nov 14, 2024	BUY	$5.02 - $7.76 $17,273 - $26,702	3,441 Added 57.3%	9,446 $65,000
Q2 2024 Aug 13, 2024	BUY	$1.68 - $14.0 $10,071 - $83,930	5,995 Added 59950.0%	6,005 $37,000
Q1 2024 May 13, 2024	SELL	$1.21 - $1.86 $14,412 - $22,154	-11,911 Reduced 99.92%	10 $0
Q4 2023 Feb 09, 2024	BUY	$0.68 - $1.47 $8,099 - $17,509	11,911 Added 119110.0%	11,921 $17,000
Q1 2023 May 12, 2023	SELL	$1.35 - $2.72 $1,059 - $2,135	-785 Reduced 98.74%	10 $0
Q4 2022 Feb 08, 2023	SELL	$1.48 - $3.2 $5,011 - $10,835	-3,386 Reduced 80.99%	795 $1,000
Q3 2022 Nov 10, 2022	BUY	$3.05 - $4.08 $1,140 - $1,525	374 Added 9.82%	4,181 $13,000
Q2 2022 Aug 10, 2022	BUY	$3.13 - $5.56 $5,655 - $10,046	1,807 Added 90.35%	3,807 $12,000
Q1 2022 May 16, 2022	SELL	$3.66 - $8.0 $8,956 - $19,576	-2,447 Reduced 55.03%	2,000 $10,000
Q4 2021 Feb 14, 2022	BUY	$6.34 - $11.9 $9,173 - $17,219	1,447 Added 48.23%	4,447 $34,000
Q3 2021 Nov 15, 2021	BUY	$5.75 - $11.21 $17,250 - $33,630	3,000 New	3,000 $33,000

Others Institutions Holding CADL

# of Institutions

Shares Held

15.6M

Call Options Held

981K

Put Options Held

521K

View Full List

About Candel Therapeutics, Inc.

Ticker CADL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,891,900
Market Cap $336M
Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...

More about CADL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account